About
Monoclonal Antibodies
Areas of Focus
Categories
Biologics & BiopharmaceuticalAntibodySeattle/Pacific Northwest
Team (21)
Clinical Trials (25)
View allTotal Trials
25
As Lead Sponsor
23
As Collaborator
2
Total Enrollment
2,643
By Phase
PHASE2: 13PHASE3: 2PHASE1/PHASE2: 1PHASE2/PHASE3: 5PHASE1: 1
By Status
COMPLETED: 12TERMINATED: 3WITHDRAWN: 2SUSPENDED: 2UNKNOWN: 2NO_LONGER_AVAILABLE: 2RECRUITING: 1ACTIVE_NOT_RECRUITING: 1
Clinical Trials Pipeline23 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Today
Hover over trial bars to see details
Recent Trials
NCT06699836Lead Sponsor
A Phase 2 Study of Leronlimab in Combination With TAS-102 + Bevacizumab in Previously Treated Participants With mCRC
PHASE2Recruiting
60 participants
Started: Jun 16, 2025 · Completed: Mar 31, 2028
NCT05730673Lead Sponsor
Leronlimab in Combination With Regorafenib in Patients With CCR5+, Metastatic Colorectal Cancer
PHASE2Withdrawn
Started: Sep 20, 2022 · Completed: Aug 10, 2023
NCT04901689Collaborator
Leronlimab in Patients With Coronavirus Disease 2019 (COVID-19) With Need for Mechanical Ventilation or Extracorporeal Membrane Oxygenation
PHASE3Suspended
316 participants
Started: Oct 23, 2021 · Completed: Feb 28, 2023
NCT04901676Collaborator
Leronlimab in Moderately Ill Patients With COVID-19 Pneumonia
PHASE3Suspended
612 participants
Started: Sep 9, 2021 · Completed: Feb 28, 2023
NCT04678830Lead Sponsor
"Double Blind, Placebo Controlled Study of Safety and Efficacy of Leronlimab in Patients With Long COVID-19"
PHASE2Completed
56 participants
Started: Mar 1, 2021 · Completed: Jul 8, 2021
Locations (1)
Headquarters
Vancouver, WA, United States
Map
Loading map...